AEON Biopharma Statistics
Total Valuation
AEON Biopharma has a market cap or net worth of $7.71 million. The enterprise value is $4.09 million.
| Market Cap | 7.71M |
| Enterprise Value | 4.09M |
Important Dates
The next estimated earnings date is Friday, August 14, 2026, after market close.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AEON Biopharma has 26.31 million shares outstanding. The number of shares has increased by 1,222.46% in one year.
| Current Share Class | 26.31M |
| Shares Outstanding | 26.31M |
| Shares Change (YoY) | +1,222.46% |
| Shares Change (QoQ) | +215.04% |
| Owned by Insiders (%) | 8.81% |
| Owned by Institutions (%) | 4.32% |
| Float | 6.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.99
| Current Ratio | 0.99 |
| Quick Ratio | 0.94 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -101.93% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -629.37% |
| Weighted Average Cost of Capital (WACC) | 5.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$7.51M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.13% in the last 52 weeks. The beta is 0.61, so AEON Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -60.13% |
| 50-Day Moving Average | 0.58 |
| 200-Day Moving Average | 0.90 |
| Relative Strength Index (RSI) | 30.58 |
| Average Volume (20 Days) | 3,076,569 |
Short Selling Information
The latest short interest is 1.11 million, so 4.23% of the outstanding shares have been sold short.
| Short Interest | 1.11M |
| Short Previous Month | 177,895 |
| Short % of Shares Out | 4.23% |
| Short % of Float | 16.05% |
| Short Ratio (days to cover) | 0.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.29M |
| Pretax Income | -60.11M |
| Net Income | -60.11M |
| EBITDA | -12.26M |
| EBIT | -12.34M |
| Earnings Per Share (EPS) | -$3.15 |
Balance Sheet
The company has $6.24 million in cash and $2.63 million in debt, with a net cash position of $3.62 million or $0.14 per share.
| Cash & Cash Equivalents | 6.24M |
| Total Debt | 2.63M |
| Net Cash | 3.62M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | -16.75M |
| Book Value Per Share | -0.66 |
| Working Capital | -44,000 |
Cash Flow
| Operating Cash Flow | -12.04M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 78,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -12.04M |
| FCF Per Share | -$0.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AEON Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,222.46% |
| Shareholder Yield | -1,222.46% |
| Earnings Yield | -779.84% |
| FCF Yield | -156.14% |
Analyst Forecast
The average price target for AEON Biopharma is $6.70, which is 2,186.69% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.70 |
| Price Target Difference | 2,186.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 26, 2025. It was a reverse split with a ratio of 1:72.
| Last Split Date | Feb 26, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:72 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |